期刊
JOURNAL OF IMMUNOLOGY
卷 188, 期 8, 页码 3869-3875出版社
AMER ASSOC IMMUNOLOGISTS
DOI: 10.4049/jimmunol.1103627
关键词
-
类别
资金
- National Institutes of Health [U19AI070352, R01NS024247, P01AI03971, P01NS038037]
- Ministerio de Educacion y Ciencia/Fulbright y Catedras Principe de Asturias
- Agencia de Gestio d'Ajuts Universitaris i de Recerca
- Commission for Universities and Research of the Ministry of Innovation, Universities and Enterprise of the Autonomous Government of Catalonia
- European Union
T cell Ig and ITIM domain (TIGIT) is a newly identified receptor expressed on T cells that binds to CD155 on the dendritic cell surface, driving them to a more tolerogenic phenotype. Given that TIGIT contains an ITIM motif in its intracellular domain and considering the potential importance of the TIGIT/CD226 pathway in human autoimmune disease, we investigated the specific role of TIGIT in human CD4(+) T cells. Using an agonistic anti-TIGIT mAb, we demonstrate a direct inhibitory effect on T cell proliferation with a decrease in expression of T-bet, GATA3, IFN regulatory factor 4, and retinoic acid-related orphan receptor c with inhibition of cytokine production, predominantly IFN-gamma. Knockdown of TIGIT expression by short hairpin RNA resulted in an increase of both T-bet and IFN-gamma mRNA and protein expression with concomitant decrease in IL-10 expression. Increases in IFN-gamma with TIGIT knockdown could be overcome by blocking CD226 signaling, indicating that TIGIT exerts immunosuppressive effects by competing with CD226 for the same CD155 ligand. These data demonstrate that TIGIT can inhibit T cell functions by competing with CD226 and can also directly inhibit T cells in a T cell-intrinsic manner. Our results provide evidence for a novel role of this alternative costimulatory pathway in regulating human T cell responses associated with autoimmune disease. The Journal of Immunology, 2012, 188: 3869-3875.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据